Boston Scientific Corp.
Marlborough, MA 01752
Share:
Promus PREMIER(TM) Everolimus-Eluting Platinum Chromium Stent System Receives CE Mark Approval
The Next Advance in Durable Polymer Stent Technology from Boston Scientific is Now Available in Europe and Other Select Geographies NATICK, Mass. - Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Promus PREMIER(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's next-generation durable polymer drug-eluting stent (DES) technology, and is...
Read More »Boston Scientific Purchases Prostate Treatment Technology from Celsion Corporation
Deal Follows Successful Four-Year Exclusive Distribution of Prolieve-® Thermodilatation System NATICK, Mass., June 21 - Boston Scientific Corporation (NYSE:BSX) today announced that it has purchased technology for treating symptomatic benign prostatic hyperplasia (BPH, often referred to as enlarged prostate) from Celsion Corporation (AMEX:CLN), following approval of the acquisition by Celsion...
Read More »Neuromodulation Device stimulates spinal cord.
Used to treat chronic pain of trunk, back, and limbs, Precision Plus(TM) Spinal Cord Stimulation System incorporates EGL Scan(TM) (Electronically Generated Lead Scan) technology that displays relative position of implanted leads without using fluoroscopy or x-ray. Neuromodulation device comes with cordless remote control and charger that features continuous temperature monitoring.
Read More »Boston Scientific Receives CE Mark for TAXUS-® Liberte(TM) Long Stent
Longest drug-eluting stent approved for the management of patients with clinically challenging coronary artery disease NATICK, Mass., and BARCELONA, Spain, May 24 /- Boston Scientific Corporation (NYSE:BSX) today announced that it has received CE Mark for its TAXUS-® Liberte(TM) Long paclitaxel-eluting coronary stent system, allowing doctors to treat longer coronary artery lesions with a single...
Read More »Visualization System is used to examine bile duct.
SpyGlass(TM) Direct Visualization System for duodenoscope assisted cholangiopancreatoscopy enables direct visualization of all bile-duct quadrants. It provides 4-way steerability and irrigation channels as well as 1.2 mm working channel through which diagnostic and therapeutic devices can be used. Miniature 6,000-pixel fiber-optic probe that attaches to camera head is inserted through single-use...
Read More »Boston Scientific and GE Healthcare Announce the First Integration of Remote Device Information Direct to Electronic Medical Records
NATICK, Mass., Nov. 9 / - Boston Scientific Corporation (NYSE:BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's LATITUDE-® 2.0 next-generation software with LATITUDE remote data integration capabilities. LATITUDE Patient Management is the first and only remote monitoring system to provide clinicians with direct device data integration capability...
Read More »Boston Scientific Receives CE Mark for Artisan(TM) Surgical Lead for Use with Neurostimulation Device to Treat Chronic Pain
Innovative Technology Makes Precision(TM) Spinal Cord Stimulator Accessible to More Patients NATICK, Mass., Nov. 3 // -- Boston Scientific Corporation (NYSE:BSX) today announced that it has received the European CE Mark for its new Artisan(TM) 2x8 Surgical Lead for use with the Precision(TM) Spinal Cord Stimulation (SCS) System. This surgical or paddle lead potentially expands the application of...
Read More »Defibrillators promote fine-tune heart synchronization.
CONTAK RENEWALÃ-®, RENEWAL 3, and RENEWAL 3 RF cardiac resynchronization therapy defibrillators (CRT-D) are available with FDA-approved Left Ventricular (LV) Offset software, which lets physicians adjust delay between right and left ventricular pacing. Able to operate on ZOOMÃ-® LATITUDE(TM) programmer, LV Offset feature can be enabled during routine, in-clinic patient visit.
Read More »Boston Scientific Becomes only Company with Two Drug-Eluting Stent Platforms with European Approval of Everolimus-Eluting PROMUS(TM) Stent System
PROMUS stent to complement Company's market-leading TAXUS-® stent systems NATICK, Mass., Oct. 16 // -- Boston Scientific Corporation (NYSE:BSX) announced today that the PROMUS(TM) Everolimus-Eluting Coronary Stent System has received CE Mark approval, making Boston Scientific the only company to offer two distinct approved drug-eluting stent (DES) platforms in the CE geographies. This approval...
Read More »Visualization System facilitates cardiac surgical ablation.
Used in conjunction with FLEX 10Ã-® surgical ablation probe, FLEXView(TM) System enables physicians to perform stand-alone ablation procedures in closed chest environment with direct visualization of procedure at all times. Surgeons can also perform unilateral ablation, minimizing invasiveness of procedure. Specialized routing and retrieval tools can cut overall procedure by 30 minutes or...
Read More »Boston Scientific Announces Acquisition of The LumenR⢠Tissue Retractor System
Technology to Improve Management of Gastrointestinal Diseases MARLBOROUGH, Mass., Nov. 3, 2016 - Boston Scientific (NYSE: BSX) today announced the acquisition of the LumenR™ Tissue Retractor System from LumenR LLC, a privately held Newark, California based company. The LumenR Tissue Retractor System is currently in development for use during endoscopic resection of lesions in the colon,...
Read More »Boston Scientific Announces Additional Investment and Right to Acquire MValve Technologies
Investment continues alliance for percutaneous mitral valve replacement established in 2012 MARLBOROUGH, Mass. and HERZLIYA, Israel - Boston Scientific Corporation (NYSE: BSX) today announced that it has closed on an additional round of financing with MValve Technologies Ltd., a developer of a percutaneous mitral valve replacement system, designed to work with the Boston Scientific LOTUS™...
Read More »Boston Scientific Closes Acquisition of the American Medical Systems Male Urology Portfolio
MARLBOROUGH, Mass. - Boston Scientific Corporation (NYSE: BSX) has closed on the previously announced agreement with Endo International plc (NASDAQ: ENDP) (TSX: ENL) to purchase American Medical Systems' (AMS) Men's Health and Prostate Health businesses, for $1.6 billion in up-front cash and a potential additional $50 million milestone based on 2016 sales. The acquisition positions Boston...
Read More »Boston Scientific Agrees to Acquire Xlumena
MARLBOROUGH, Mass. and MOUNTAIN VIEW, Calif. –Ã- Boston Scientific Corporation (NYSE: BSX) announces that it has signed a definitive agreement to acquire Xlumena, Inc., a venture-backed medical device company that develops, manufactures and sells minimally invasive devices for Endoscopic Ultrasound (EUS) guided transluminal drainage of targeted areas within the gastrointestinal tract. The...
Read More »Promus PREMIER(TM) Everolimus-Eluting Platinum Chromium Stent System Receives CE Mark Approval
The Next Advance in Durable Polymer Stent Technology from Boston Scientific is Now Available in Europe and Other Select Geographies NATICK, Mass. - Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Promus PREMIER(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's next-generation durable polymer drug-eluting stent (DES) technology, and is...
Read More »Boston Scientific Announces Its ACC 2011 Schedule
Clinical presentations to include 12-month data on PROMUS Element(TM) Platinum Chromium Stent NATICK, Mass., March 29, 2011 - Boston Scientific Corporation (NYSE: BSX) today announced its clinical trial news and events schedule at the 60th Annual Scientific Session of the American College of Cardiology/i2 Summit, April 2-5, 2011 in New Orleans. Twelve-month results from the PLATINUM Workhorse...
Read More »Boston Scientific to Webcast Analyst Event
NATICK, Mass., March 22, 2011 - Boston Scientific Corporation (NYSE: BSX) today announced that it will hold an analyst event on April 4, 2011 at the 60th Annual Scientific Session of the American College of Cardiology/i2 Summit in New Orleans. The Company will provide an update on its Cardiology, Rhythm and Vascular (CRV) Group initiatives involving coronary stent and structural heart...
Read More »Boston Scientific to Present at Barclays Capital 2011 Global Healthcare Conference
NATICK, Mass., March 8, 2011 -- Boston Scientific Corporation (NYSE: BSX) is scheduled to present at the Barclays Capital 2011 Global Healthcare Conference in Miami. Jeff Capello, Executive Vice President and Chief Financial Officer, will make a 25-minute presentation on Tuesday, March 15, 2011. The presentation is scheduled to begin at 8:30 a.m. ET. A live webcast of the presentation will be...
Read More »Boston Scientific to Acquire Atritech
Innovative left atrial appendage closure device offers alternative for patients with atrial fibrillation and strengthens Company's position in emerging structural heart markets NATICK, Mass., Jan. 19, 2011 - Boston Scientific Corporation (NYSE: BSX) today announced the signing of a definitive merger agreement, under which the Company will acquire Atritech, Inc., a privately held company based in...
Read More »Boston Scientific Acquires Intelect Medical
Innovative technology designed to advance deep brain stimulation therapy NATICK and BOSTON, Mass., Jan. 5, 2011 - Boston Scientific Corporation (NYSE: BSX) today announced it has acquired Intelect Medical, Inc., a development-stage company located in Boston. Intelect Medical is developing advanced neuromodulation technologies for deep brain stimulation (DBS) therapy. The transaction values...
Read More »